 |
 |
|
|
|
Immunohistochemical analyses provide critical
diagnosis for multiple diseases. Monoclonal
antibody availability and tissue specific diagnostic
panels are available as needed. Disease
specific panels for prognostication are established
for breast cancer, colorectal cancer, and other
neoplasms.
|
|
|
|
|
|
|
|
Download our Tests -- Organized by how you use them
Alphabetical Test List
(28k) or by Test #
- with reference #
Test list by the
type of disease testing (155k)
- with reference #, Test Type and Description
Tests Details
(425k)
- alphabetical with reference #, Test Type,
Includes, CPT Codes, Descriptions, and Disease/Specialty cross reference.
We are happy to take recommendations on how our test lists could be organized
to better communicate how we might solve your patients' needs. Call us.
Tests By Type
|
ref# |
Test Type |
Test Name |
CPT code |
Includes |
Description |
Clinical Significance |
|
15 |
IHC |
Breast Panel |
88342(5), 88361(5) |
ER, PR, P53, Ki-67, HER2 & Interpretation |
Tumor morphometric analysis- Includes ER, PR,
HER-2/neu, p53, and Ki67; can be used with FISH
for HER-2/neu amplification assay |
Breast cancer management includes: ER/PR, HER-2/neu
(FISH and IHC), p53, Ki67 (proliferation). |
|
34 |
IHC |
Epidermal Growth Factor Receptor (EGFR)
|
88342(1), 88361(1) |
Immunocytochemistry, Morphometric Analysis |
The epidermal growth factor (EGF) and its
receptor, EGFR, have been identified as key
drivers in the process of cell growth and
replication. Increased activity at the EGFR
receptor results in uncontrolled cell
proliferation and has been implicated in a
variety of solid tumors, including colorectal
tumors, head and neck carcinomas, and in some
lung tumors. Excessive activation of EGFR is
also known to be associated with advanced stages
of cancer and a poor prognosis for the patient.
Erbitux is a monoclonal antibody that binds to
EGFR resulting in inhibition of tumor cell
growth, survival and progression. |
EGFR pharmDx™ is indicated as an aid in
identifying colorectal cancer in patients
eligible for treatment with ERBITUX™ (cetuximab).
|
Tests By Type
|
ref# |
Test Type |
Test Name |
CPT code |
Includes |
Description |
Clinical Significance |
Normal Ranges |
Specimen |
|
31 |
Digital Image Analysis |
DNA Ploidy |
88358 (1) |
Consultation and report, morphometric analysis
(tumor) |
DNA content and cell cycle analysis in solid
tumors- paraffin tissue |
In breast cancer and other solid tumors, many
studies indicate that low S-phase and diploid
DNA content are associated with a relatively
good prognosis. Conversely, the presence of
aneuploid DNA content and a high S-phase tends
to correlate with a worse prognosis.
|
Diploid DNA content |
|
|
 |
|
TEST SCHEDULES
